Status:
ENROLLING_BY_INVITATION
Clinical and Neurophysiological Effects of tDCS on Depression in Parkinson's Disease
Lead Sponsor:
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Conditions:
PARKINSON DISEASE (Disorder)
Eligibility:
All Genders
35-75 years
Phase:
NA
Brief Summary
Parkinson's disease (PD) is the second most common neurodegenerative disorder, characterized by dopaminergic cell degeneration leading to neurophysiological alterations and a heterogeneous clinical pr...
Eligibility Criteria
Inclusion
- Diagnosis of idiopathic Parkinson's disease according to the clinical diagnostic criteria of the Movement Disorder Society;
- No dementia (Montreal Cognitive Assessment score ≥ 22/30);
- Presence of depressive symptoms
- Pharmacological treatment for motor symptoms stable for at least 1 month
- Treatment (pharmacological/non-pharmacological) for depressive symptoms stable for at least 3 months.
Exclusion
- Patients with a pacemaker, intracranial electrodes, implanted defibrillators, or any other type of prosthesis;
- Patients undergoing Deep Brain Stimulation treatment;
- Patients with epilepsy or a history of seizures;
- Patients with psychosis;
- Patients with a history of skull fracture;
- Pregnant/breastfeeding patients;
- Patients with suicidal ideation or a suicide attempt in the six months prior to the start of the study;
- Patients with a history of substance dependence or abuse;
- Concomitant treatment with medications that may affect tDCS (benzodiazepines, anticonvulsants, pseudoephedrine, dextromethorphan).
Key Trial Info
Start Date :
April 23 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 1 2027
Estimated Enrollment :
52 Patients enrolled
Trial Details
Trial ID
NCT06885138
Start Date
April 23 2024
End Date
February 1 2027
Last Update
March 20 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Milan, Italy, 20122